<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927325</url>
  </required_header>
  <id_info>
    <org_study_id>1165/2021</org_study_id>
    <nct_id>NCT04927325</nct_id>
  </id_info>
  <brief_title>Erythema at Exit Site &amp; Tablet Camera</brief_title>
  <official_title>Quantification of Erythema at Exit Site of Central Catheter: Is a Tablet Camera Sufficient?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: In critical care medicine central venous catheters play an important role in the&#xD;
      source of infections. In the daily routine prior to the diagnosis the suspicion of catheter&#xD;
      related infection is discussed in the medical team due to signs of systemic inflammation or&#xD;
      exit site infection like erythema, induration or tenderness. However, if an erythema at exit&#xD;
      site of a central line can be quantified with a tablet camera, is unknown.&#xD;
&#xD;
      Methods: Standardized set of photos will be taken of 10 central lines with a reddened exit&#xD;
      site and 10 catheters without an erythema (as a control over time) with a tablet camera and a&#xD;
      single-lens reflex camera. The percentage of usable images between tablet and single-lens&#xD;
      reflex camera will be analysed. Furthermore, two independent clinical experts from&#xD;
      dermatology will grade blinded de-identied images on a scale from 0 to 4 (0 - no erythema, 1-&#xD;
      very faint, 2 - faint, 3 - bright, 4 - very bright).&#xD;
&#xD;
      Objectives: The primary objective of this feasibility study aims to analyze the reliability&#xD;
      of a tablet camera as a device for quantification of erythema around an exit site.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>10 central lines with a reddened exit site 10 central lines without a reddened exit site</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of usable images</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>The percentage of useable images of tablet camera compared with single-lens reflex (SLR) camera will be analysed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of the exit site with regards to an erythema scale</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>The secondary objective aims to evaluate the quantification of the exit site regarding to the erythema scale by two independent clinical experts comparing images of tablet and SLR camera.&#xD;
The erythema will be graded using a visual ordinal scale (grade 0 to grade 4). Grade 0 represents no erythema, whereas grade 4 describes a very bright erythema.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CLABSI - Central Line Associated Bloodstream Infection</condition>
  <condition>CRBSI - Catheter Related Bloodstream Infection</condition>
  <condition>Digital Technology</condition>
  <arm_group>
    <arm_group_label>central line with a reddened exit site</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A standardized set of photos will be taken of 10 central lines with an erythema at exit site (visible to the naked eye)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group: central line without a reddened exit site</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A standardized set of photos will be taken of 10 newly inserted CVC (as a control over time to evaluate the in-patient redness and the impact of irritation of a CVC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Set of Photos</intervention_name>
    <description>A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.</description>
    <arm_group_label>Control Group: central line without a reddened exit site</arm_group_label>
    <arm_group_label>central line with a reddened exit site</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult&#xD;
&#xD;
          -  Jugular CVC or Subclavian CVC&#xD;
&#xD;
          -  ICU-Admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years&#xD;
&#xD;
          -  Pregnancy/Lactation&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  neutropenia (&lt;1000/m3)&#xD;
&#xD;
          -  hematologic tumor&#xD;
&#xD;
          -  dark pigmentation&#xD;
&#xD;
          -  prone position within the last 24 hours&#xD;
&#xD;
          -  head/neck-area: cancer, operation, burns or radiation, tattoos&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Department of Anaesthesia &amp; General Intensive Care</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Hafner, MD, PhD</last_name>
    <phone>+4314040041000</phone>
    <email>christina.hafner@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harald Willschke, MD, MSc</last_name>
    <phone>+4314040041000</phone>
    <email>harald.willschke@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesia, General Intensive Care and Pain Management,Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Hafner</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Christina Hafner</investigator_full_name>
    <investigator_title>Clinical Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

